Postdoctoral Fellow, Multiple Myeloma Immuno-Oncology, Oncology Bioscience

Characterise how inhibiting a first-in-class kinase target drives multiple myeloma regression through both tumour-intrinsic signalling and engagement of the innate immune system. Using a selective AstraZeneca compound and in vivo models, the postdoc identifies the innate immune cell types responsible and the underlying mechanism.

PhD in immunology, haematology, cancer biology, molecular or cell biology or a related field, awarded within the last four years (or conferred within six months of joining). Stated compensation USD 99,900-120,000 plus short-term incentive.